Gross profit increase of 105% to GBP14.0 million (2007: GBP6.9 million).

Operating loss decrease of 49% to GBP3.2 million (2007: GBP6.2 million).

Net funds at 31 December 2008 of GBP33.6m (2007: GBP34.3m).

US launch of Medtronic’s Endeavor Drug-Eluting Stent.

Completion of recruitment in the Dermal Filler Bead trial.

FDA approval of PARAGON I trial.

Proposed dividend, based on royalty income.

Drug-Eluting Beads Japan Option Agreement with Eisai.

Acquisition of BrachySciences.

Final PRECISION V data announced at CIRSE.

Clinical Collaboration agreement with Bayer.

First patient treated in the CellBeadsTM stroke trial.

GLP-1 Development and Option Agreement with AstraZeneca.

Post Period Highlights

Clinical Trial under way in UK in Liver Metastases from Colorectal Cancer.

Financial guidance re-confirmed.

Principal 2009 Operating Goals:


First patient treated in Bayer’s, “SPACE”, trial (Drug-Eluting Bead +/- Nexavar in HCC).

Launch of DC Bead in China.

Presentation of data from the Drug-Eluting Bead Surgical Registry at The American Hepato-Pancreato-Biliary Accociation Annual Meeting (12-15 March, Miami Beach, Florida).

AstraZeneca programme progress.

Completion of recruitment in the CellBeads stroke trial.


Revenue in the range GBP22 million to GBP24 million.

Closing net funds of GBP27 million after payment of the dividend of GBP2 million.

Payment of 5 pence per share dividend in May.